The specialist cancer drug discovery and development business has released H1 Dec 2018 results. Chk1 remains the key short-term value driver and potential source of cash flow. Sareum’s licensing partner Sierra Oncology (NASDAQ:SRRA) is spearheading the push to commercialise SRA737 as a best in class oncology therapy focussed on disabling cancer cells’ DNA damage repair (DDR) capabilities. It has made excellent progress in the dose escalation portions of both the monotherapy, and l
